Sagimet Biosciences announced its management will participate in the Leerink Partners Therapeutics Forum on July 15, 2026, to engage with investors. The company also granted 34,300 stock options to two newly hired employees as an inducement under Nasdaq Listing Rule 5635(c)(4). These options have a ten-year term, vest over four years, and are priced at the closing stock price on June 22, 2026. Sagimet focuses on developing novel therapies targeting metabolic and fibrotic diseases linked to fatty acid production.
In 2025, AI-related companies raised at least $200 billion in debt to finance data center buildouts, marking one of the largest tech sector financing efforts ever. Financial expert Jim Rickards highlights that much of this debt is held through comple...
Celtic Lux Holdings, formerly Alvogen Lux Holdings, purchased 10,133,333 shares of Alvotech at $3.75 per share on June 16, 2026. This transaction was reported to the Luxembourg financial regulator, CSSF, indicating significant insider activity. The p...
FTI Consulting appointed Jerome Nyssen as Senior Managing Director in its Risk Advisory practice in Australia to enhance AI-driven risk, compliance, and governance services. Nyssen brings 25 years of experience across financial services and technolog...
General Fusion has made significant progress with its LM26 Magnetized Target Fusion machine, achieving plasma electron temperatures of about 8.4 million degrees Celsius (0.72 keV), nearing its 1 keV target. This milestone demonstrates effective plasm...
Bitcoin's futures market saw a significant 19.5% drop in Open Interest from $26 billion to $20.89 billion in June, outpacing the 11.4% price decline. This suggests traders are reducing leveraged positions, leading to a healthier market structure with...
